Preventive effect of urinary trypsin inhibitor on the development of liver fibrosis in mice

Experimental Biology and Medicine

Volumn 236, Issue 11, 2011, Pages 1314-1321

  Kono, Toru ^a   Kashiwade, Yurino ^a   Asama, Toshiyuki ^a   Chisato, Naoyuki ^a   Ebisawa, Yoshiaki ^a   Yoneda, Masashi ^b   Kasai, Shinichi ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Knockout mice; Liver fibrosis; TGF ; Ulinastatin; Urinary trypsin inhibitor

Indexed keywords

HYALURONIC ACID; TRANSFORMING GROWTH FACTOR BETA; ULINASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; LIVER FIBROSIS; MOUSE; NONHUMAN; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN SYNTHESIS;

ANIMALS; FEMALE; GLYCOPROTEINS; HYALURONIC ACID; LIVER; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, KNOCKOUT; TRANSFORMING GROWTH FACTOR BETA;

MUS;

EID: 80055108355     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2011.011173     Document Type: Article

References (49)

1. Salier JP, Diarra-Mehrpour M, Sesboue R, Bourguignon J, Benarous R, Ohkubo I, Kurachi S, Kurachi K, Martin JP. Isolation and characterization of cDNAs encoding the heavy chain of human inter-alpha-trypsin inhibitor (I alpha TI): unambiguous evidence for multipolypeptide chain structure of I alpha TI. Proc Natl Acad Sci USA 1987;84:8272-6
2. Kaumeyer JF, Polazzi JO, Kotick MP. The mRNA for a proteinase inhibitor related to the HI-30 domain of inter-alpha-trypsin inhibitor also encodes alpha-1-microglobulin (protein HC). Nucleic Acids Res 1986;14:7839-50
3. Inoue K, Takano H. Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders. Expert Opin Investig Drugs 2010;19:513-20
4. Hoogerwerf WA. Pharmacological management of pancreatitis. Curr Opin Pharmacol 2005;5:578-82
5. Yamaguchi Y, Ohshiro H, Nagao Y, Odawara K, Okabe K, Hidaka H, Ishihara K, Uchino S, Furuhashi T, Yamada S, Mori K, Ogawa M. Urinary trypsin inhibitor reduces C-X-C chemokine production in rat liver ischemia/reperfusion. J Surg Res 2000;94:107-15
6. Okuhama Y, Shiraishi M, Higa T, Tomori H, Taira K, Mamadi T, Muto Y. Protective effects of ulinastatin against ischemia-reperfusion injury. J Surg Res 1999;82:34-42
7. Brenner DA, Veloz L, Jaenisch R, Alcorn JM. Stimulation of the collagen alpha 1 (I) endogenous gene and transgene in carbon tetrachloride-induced hepatic fibrosis. Hepatology 1993;17:287-92
8. Kudo Y, Egashira T, Yamanaka Y. Protective effect of ulinastatin against liver injury caused by ischemia-reperfusion in rats. Jpn J Pharmacol 1992;60:239-45
9. Sjoberg EM, Fries E. Biosynthesis of bikunin (urinary trypsin inhibitor) in rat hepatocytes. Arch Biochem Biophys 1992;295:217-22
10. Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med (Maywood) 2008;233:109-22
11. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18
12. Akita K, Okuno M, Enya M, Imai S, Moriwaki H, Kawada N, Suzuki Y, Kojima S. Impaired liver regeneration in mice by lipopolysaccharide via TNF-alpha/kallikrein-mediated activation of latent TGF-beta. Gastroenterology 2002;123:352-64
13. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003;116:217-24
14. Okuno M, Akita K, Moriwaki H, Kawada N, Ikeda K, Kaneda K, Suzuki Y, Kojima S. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology 2001;120:1784-800
15. Ueki M, Taie S, Chujo K, Asaga T, Iwanaga Y, Ono J, Maekawa N. Urinary trypsin inhibitor reduces inflammatory response in kidney induced by lipopolysaccharide. J Biosci Bioeng 2007;104:315-20
16. Tsujino T, Kawabe T, Omata M. Antiproteases in preventing post-ERCP acute pancreatitis. JOP 2007;8:509-17
17. Katoh H, Ishikawa H, Hasegawa M, Yoshida Y, Suzuki Y, Ohno T, Takahashi T, Nakano T. Protective effect of urinary trypsin inhibitor on the development of radiation-induced lung fibrosis in mice. J Radiat Res (Tokyo) 2010;51:325-32
18. Kato Y, Kudo M, Shinkawa T, Mochizuki H, Isaji M, Shiromizu I, Hoshida K. Role of O-linked carbohydrate of human urinary trypsin inhibitor on its lysosomal membrane-stabilizing property. Biochem Biophys Res Commun 1998;243:377-83
19. Takano H, Inoue K, Shimada A, Sato H, Yanagisawa R, Yoshikawa T. Urinary trypsin inhibitor protects against liver injury and coagulation pathway dysregulation induced by lipopolysaccharide/D-galactosamine in mice. Lab Invest 2009;89:833-9
20. Itabashi K, Ito Y, Takahashi T, Ishii K, Sato K, Kakita A. Protective effects of urinary trypsin inhibitor (UTI) on hepatic microvasculature in hypotensive brain-dead rats. Eur Surg Res 2002;34:330-8
21. Li XK, Matin AF, Suzuki H, Uno T, Yamaguchi T, Harada Y. Effect of protease inhibitor on ischemia/reperfusion injury of the rat liver. Transplantation 1993;56:1331-6
22. Salguero Palacios R, Roderfeld M, Hemmann S, Rath T, Atanasova S, Tschuschner A, Gressner OA, Weiskirchen R, Graf J, Roeb E. Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide-induced hepatic fibrosis in mice. Lab Invest 2008;88:1192-203
23. Sato H, Kajikawa S, Kuroda S, Horisawa Y, Nakamura N, Kaga N, Kakinuma C, Kato K, Morishita H, Niwa H, Miyazaki J. Impaired fertility in female mice lacking urinary trypsin inhibitor. Biochem Biophys Res Commun 2001;281:1154-60
24. Muller A, Machnik F, Zimmermann T, Schubert H. Thioacetamide-induced cirrhosis-like liver lesions in rats -usefulness and reliability of this animal model. Exp Pathol 1988;34:229-36
25. Wu XL, Zeng WZ, Wang PL, Lei CT, Jiang MD, Chen XB, Zhang Y, Xu H, Wang Z. Effect of compound rhodiola sachalinensis A Bor on CCl4-induced liver fibrosis in rats and its probable molecular mechanisms. World J Gastroenterol 2003;9:1559-62
26. Hung KS, Lee TH, Chou WY, Wu CL, Cho CL, Lu CN, Jawan B, Wang CH. Interleukin-10 gene therapy reverses thioacetamide-induced liver fibrosis in mice. Biochem Biophys Res Commun 2005;336:324-31
27. Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, Qian T, Schoonhoven R, Hagedorn CH, Lemasters JJ, Brenner DA. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003;112:1383-94
28. Chevallier M, Guerret S, Chossegros P, Gerard F, Grimaud JA. A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies. Hepatology 1994;20:349-55
29. Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993;328:1828-35
30. Breitkopf K, Haas S, Wiercinska E, Singer MV, Dooley S. Anti-TGF-beta strategies for the treatment of chronic liver disease. Alcohol Clin Exp Res 2005;29:121S-131S
31. Marek A, Brodzicki J, Liberek A, Korzon M. TGF-beta (transforming growth factor-beta) in chronic inflammatory conditions - a new diagnostic and prognostic marker? Med Sci Monit 2002;8:RA145-51
32. Okuno M, Moriwaki H, Imai S, Muto Y, Kawada N, Suzuki Y, Kojima S. Retinoids exacerbate rat liver fibrosis by inducing the activation of latent TGF-beta in liver stellate cells. Hepatology 1997;26:913-21
33. Okuno M, Moriwaki H, Muto Y, Kojima S. Protease inhibitors suppress TGF-beta generation by hepatic stellate cells. J Hepatol 1998;29:1031-2
34. Okuno M, Sato T, Kitamoto T, Imai S, Kawada N, Suzuki Y, Yoshimura H, Moriwaki H, Onuki K, Masushige S, Muto Y, Friedman SL, Kato S, Kojima S. Increased 9,13-di-cis-retinoic acid in rat hepatic fibrosis: implication for a potential link between retinoid loss and TGF-beta mediated fibrogenesis in vivo. J Hepatol 1999;30:1073-80
35. Braulio VB, Kouyoumdjian M, Zucoloto S, Figueiredo F, Borges DR. Plasma-kallikrein clearance during liver regeneration after partial hepatectomy in the rat. Liver 1998;18:371-7
36. Schnur J, Olah J, Szepesi A, Nagy P, Thorgeirsson SS. Thioacetamide-induced hepatic fibrosis in transforming growth factor beta-1 transgenic mice. Eur J Gastroenterol Hepatol 2004;16:127-33
37. Kamiya K, Kono T, Iwamoto J, Yoneda M, Kotani H, Kasai S. The cytoprotective role of lipopolysaccharide-induced nitric oxide against liver damage during early phase of endotoxemia in rats. Shock 2000;14:229-33
38. Jacob AI, Goldberg PK, Bloom N, Degenshein GA, Kozinn PJ. Endotoxin and bacteria in portal blood. Gastroenterology 1977;72:1268-70
39. Nolan JP. Endotoxin, reticuloendothelial function, and liver injury. Hepatology 1981;1:458-65
40. Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology 1988;8:232-6
41. Tarao K, So K, Moroi T, Ikeuchi T, Suyama T. Detection of endotoxin in plasma and ascitic fluid of patients with cirrhosis: its clinical significance. Gastroenterology 1977;73:539-42
42. Liu X, Hu H, Yin JQ. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int 2006;26:8-22
43. Natarajan SK, Thomas S, Ramamoorthy P, Basivireddy J, Pulimood AB, Ramachandran A, Balasubramanian KA. Oxidative stress in the development of liver cirrhosis: a comparison of two different experimental models. J Gastroenterol Hepatol 2006;21:947-57
44. Strnad P, Tao GZ, Zhou Q, Harada M, Toivola DM, Brunt EM, Omary MB. Keratin mutation predisposes to mouse liver fibrosis and unmasks differential effects of the carbon tetrachloride and thioacetamide models. Gastroenterology 2008;134:1169-79
45. Thogersen IB, Enghild JJ. Biosynthesis of bikunin proteins in the human carcinoma cell line HepG2 and in primary human hepatocytes. Polypeptide assembly by glycosaminoglycan. J Biol Chem 1995;270:18700-9
46. Zhao M, Yoneda M, Ohashi Y, Kurono S, Iwata H, Ohnuki Y, Kimata K. Evidence for the covalent binding of SHAP, heavy chains of inter-alpha-trypsin inhibitor, to hyaluronan. J Biol Chem 1995;270:26657-63
47. McDonald B, McAvoy EF, Lam F, Gill V, de la Motte C, Savani RC, Kubes P. Interaction of CD44 and hyaluronan is the dominant mechanism for neutrophil sequestration in inflamed liver sinusoids. J Exp Med 2008;205:915-27
48. Shen L, Zhuo L, Okumura A, Ishikawa T, Miyachi M, Owa Y, Ishizawa T, Sugiura N, Nagata Y, Nonami T, Kakumu S, Kimata K. The SHAP-hyaluronan complex in serum from patients with chronic liver diseases caused by hepatitis virus infection. Hepatol Res 2006;34:178-86
49. Zhu L, Zhuo L, Kimata K, Yamaguchi E, Watanabe H, Aronica MA, Hascall VC, Baba K. Deficiency in the serum-derived hyaluronan-associated protein-hyaluronan complex enhances airwayhyperresponsiveness in a murine model of asthma. Int Arch Allergy Immunol 2010;153:223-33